Histological assessment of inflammatory infiltrates in interstitial cystitis/bladder pain syndrome (IC/BPS): a comparative study of mast cell quantification techniques [Abstract]

Conference item


Akmandor, T. and Freeman, A. 2025. Histological assessment of inflammatory infiltrates in interstitial cystitis/bladder pain syndrome (IC/BPS): a comparative study of mast cell quantification techniques [Abstract]. Medicine 2025: The Future of Medicine. RCP Annual Conference. London, UK 02 - 03 Jun 2025 Elsevier. https://doi.org/10.1016/j.clinme.2025.100405
TitleHistological assessment of inflammatory infiltrates in interstitial cystitis/bladder pain syndrome (IC/BPS): a comparative study of mast cell quantification techniques [Abstract]
AuthorsAkmandor, T. and Freeman, A.
Abstract

Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic disease of unknown aetiology that affects the normal pathophysiology of urinary bladder.1 Given the complex nature of pathogenesis, there are no universally accepted clinical or histological diagnostic criteria for IC/BPS. The central role of urothelial inflammation and mast cell activation in the detrusor muscle have been histologically confirmed in IC/BPS cases.2,3 However, there is no standardised diagnostic technique for evaluating, interpreting and reporting histopathological findings, such as inflammatory markers, in IC/BPS. Therefore, this retrospective study aimed to assess inflammatory cell infiltrate to better understand the role of inflammation to provide diagnostic value in histopathology reports for improved patient treatment and to compare histochemical and immunohistochemical stains for efficiency and sensitivity in detection and quantification of mast cells in detrusor muscle.

Methods
This retrospective study analysed 26 formalin-fixed paraffin-embedded bladder biopsies/tissues with confirmed IC/BPS. Inflammation was graded as acute, chronic or mix based on present inflammatory cells using Haematoxylin and Eosin staining. Eosinophils were recorded as present or absent. Mast cells were detected using three techniques: Toluidine Blue, Artisan Giemsa, and anti-CD117 immunohistochemistry. A four-point grading system (0: <5, 1: 6–10, 2: 11–20, 3: >20 mast cells/high-power field) was applied. Sensitivity was calculated based on positive mast cell detection. Lymphocyte subsets were assessed using anti-CD3 (T lymphocytes) and anti-CD20 (B lymphocytes) antibodies, and predominance was recorded in cases with moderate-to-severe inflammation.

Results
Chronic inflammation was observed in 96.2% of cases, with eosinophilic infiltration present in 76.9% (Fig 1). CD117 immunohistochemistry demonstrated the highest sensitivity for mast cell detection (73.1%) compared with Toluidine Blue (50%) and Artisan Giemsa (26.9%) (p=0.002) (Fig 2). Definite mast cell infiltration was found in 46.2% of cases, all of which were eosinophil-positive. Among these, 83.3% showed T lymphocyte predominance within the detrusor muscle. These results suggest that eosinophils and T-lymphocytes may have a synergistic role in chronic bladder inflammation.

Conclusion
This study confirmed the importance of inflammatory cell infiltrates, particularly lymphoplasmacytic, eosinophilic and mast cell components, in the histological evaluation of IC/BPS, consistent with published studies.1–5 Anti-CD117 staining was the most sensitive and reproducible method for detecting mast cells, supporting its inclusion in routine histopathological assessment. The observed T lymphocyte predominance in mast cell-positive, eosinophil-rich cases suggests a potential immunological pattern that may inform future diagnostic and therapeutic strategies. Standardising the evaluation of inflammatory infiltrates and including mast cell and lymphocyte profiling in pathology reports could enhance diagnostic precision and guide patient management in IC/BPS.

Sustainable Development Goals9 Industry, innovation and infrastructure
Middlesex University ThemeHealth & Wellbeing
ConferenceMedicine 2025: The Future of Medicine. RCP Annual Conference
Proceedings TitleClinical Medicine
ISSN
Electronic1473-4893
PublisherElsevier
Publication dates
PrintJul 2025
Online24 Jul 2025
Publication process dates
AcceptedJul 2025
Deposited26 Feb 2026
Output statusPublished
Publisher's version
License
File Access Level
Open
Digital Object Identifier (DOI)https://doi.org/10.1016/j.clinme.2025.100405
Web address (URL) of conference proceedingshttps://www.sciencedirect.com/journal/clinical-medicine/vol/25/issue/4/suppl/S
Related Output
Has metadatahttps://publons.com/wos-op/publon/77090173/
Permalink -

https://repository.mdx.ac.uk/item/340vv2

Download files


Publisher's version
1-s2.0-S147021182500123X-main.pdf
License: CC BY-NC-ND 4.0
File access level: Open

  • 9
    total views
  • 5
    total downloads
  • 0
    views this month
  • 0
    downloads this month

Export as

Related outputs

Paclitaxel-loaded silica nanoparticle microneedle arrays enable sustained transdermal drug delivery for localised breast cancer therapy [Abstract]
Akmandor, T., Sully, R., Loizidou, E., Garelick, H., Podoleanu, A. and Gubala, V. 2026. Paclitaxel-loaded silica nanoparticle microneedle arrays enable sustained transdermal drug delivery for localised breast cancer therapy [Abstract]. ESMO Breast Cancer Congress 2026. Berlin, Germany 06 - 08 May 2026 Elsevier. https://doi.org/10.1016/j.esmoop.2026.107086
Molecular dynamics of PU.1 and annexin A1 in acute promyelocytic leukaemia cells following ATRA/ATO therapy
Akmandor, T. and Shi, Z. 2026. Molecular dynamics of PU.1 and annexin A1 in acute promyelocytic leukaemia cells following ATRA/ATO therapy. British Society for Haematology (BSH) 66th Annual Scientific Meeting 2026 . Liverpool, UK 18 - 21 Apr 2026 Wiley.
Transcriptional modulation of differentiation-associated markers during ATRA and ATO treatment in acute promyelocytic leukaemia cells
Akmandor, T., Tuduwage, D., Mire, M. and Shi, Z. 2026. Transcriptional modulation of differentiation-associated markers during ATRA and ATO treatment in acute promyelocytic leukaemia cells. British Society for Haematology (BSH) 66th Annual Scientific Meeting 2026 . Liverpool, UK 18 - 21 Apr 2026 Wiley.
Clinicopathological and molecular landscape of lynch-associated endometrial carcinoma undergoing surveillance: a retrospective single-centre cohort study
Akmandor, T., Scott, M., Thind, D., Ganeshram, N.P., Rosenthal, A.N. and Arora, R. 2026. Clinicopathological and molecular landscape of lynch-associated endometrial carcinoma undergoing surveillance: a retrospective single-centre cohort study. ESGO 2026 Congress. Copenhagen, Denmark 26 - 28 Feb 2026 Elsevier. https://doi.org/10.1016/j.ijgc.2025.103406
316eP Imiquimod-loaded dissolvable microneedles: a novel pre-clinical immunotherapeutic approach for dermato-oncology
Akmandor, T., Russo, C., Loizidou, E., Leontiev, D. and Hyseni, A. 2025. 316eP Imiquimod-loaded dissolvable microneedles: a novel pre-clinical immunotherapeutic approach for dermato-oncology. ESMO Immuno-Oncology Congress 2025. London, UK 10 - 12 Dec 2025 Elsevier. https://doi.org/10.1016/j.iotech.2025.101515
315eP Pre-clinical feasibility and translational challenges of cytokine-loaded dissolvable microneedles for cutaneous immunotherapy
Akmandor, T., Outram, S., Russo, C. and Loizidou, E. 2025. 315eP Pre-clinical feasibility and translational challenges of cytokine-loaded dissolvable microneedles for cutaneous immunotherapy. ESMO Immuno-Oncology Congress 2025. London, UK 10 - 12 Dec 2025 Elsevier. https://doi.org/10.1016/j.iotech.2025.101514